Case report: New treatment with Tolvaptan for heart failure after cardiac surgery

Authors

  • Akira Sezai
  • Mitsuru Iida
  • Isamu Yoshitake
  • Shunji Osaka
  • Hiroaki Hata
  • Motomi Shiono

DOI:

https://doi.org/10.1532/HSF98.2014366

Abstract

The vasopressin V2 receptor antagonist (Tolvaptan) is a new diuretic that selectively promotes the excretion of water. It has been reported to be effective for patients in cardiology, but there have been no reports of its use in the perioperative period after cardiac surgery. We report the usefulness of Tolvaptan for postoperative fluid management in a patient with severe mitral regurgitation due to ischemic cardiomyopathy. Marked improvement was achieved after administration of Tolvaptan for heart failure in the postoperative period.

References

Eshaghian S, Horwich TB, Fonarow GC. 2006. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97(12):1759-64.nGheorghiade M, Konstam MA, Burnett JC, Jr., et al. 2007. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (12);297:1332-43.nImamura T, Kunugawa K, Minatsuki S, et al. 2013. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 77(5):1208-1213.nKonstam MA, Gheorghiade M, Burnett JC, Jr., et al. 2007. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319-31.nPang PS, Gheorghiade M, Difu J, et al. 2011. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J 161(6):1067-72.nAbdel-Qadir HM, Tu JV, Yun L, et al. 2010. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160(2):264-71.nSezai A, Hata M, Niino T, et al. 2009. New treatment with human atrial natriuretic peptide for postoperative myonephropathic metabolic syndrome. Ann Thorac Surg 88(4):1333-5.nSezai A, Hata M, Niino T, et al. 2010. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery for left ventricular dysfunction. J Am Coll Cardiol 55(17):1844-51.nSezai A, Nakata K, Iida M, et al. 2013. Results of low-dose carperitide infusion in high-risk patients undergoing coronary artery bypass grafting. Ann Thorac Surg 96(1):119-26.n

Published

2014-09-01

How to Cite

Sezai, A., Iida, M., Yoshitake, I., Osaka, S., Hata, H., & Shiono, M. (2014). Case report: New treatment with Tolvaptan for heart failure after cardiac surgery. The Heart Surgery Forum, 17(4), E198-E200. https://doi.org/10.1532/HSF98.2014366

Issue

Section

Articles